Jason Rotter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason Rotter has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Justin G. Trogdon
Affiliations Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
3 shared publications Stephanie B. Wheeler
Department of Health Policy and Management Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill North Carolina
3 shared publications- Jennifer C. Spencer
Department of Population Health, Dell Medical School, University of Texas at Austin
2 shared publications - Stephanie Brooke Wheeler
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina
2 shared publications - Angela B. Smith
University of North Carolina School of Medicine, Chapel Hill, NC, USA
1 shared publication Caitlin B. Biddell
Mathematica Washington District of Columbia USA
1 shared publication
Latest Publications
- 16 July 2025
- Published by Wiley in Health Services Research
- Vol. 61 (2) , e70005
Machine Learning Risk Stratification for Older Breast Cancer Survivors: Clinical Care Implications
Objective: To develop and validate a clinical risk prediction algorithm to identify breast cancer survivors at high risk for adverse outcomes. Study Setting and Design: Our national retrospective analysis used cross‐validated random forest machine learning models to separately predict the risk of all‐cause death, cancer‐specific death, claims‐derived risk of recurrence, and other adverse health outcomes within 3 and 5 years following treatment completion. Data Sources and Analytic Sample: Our study used the Surveillance and Epidemiology End Results (SEER) registry—Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey (SEER‐CAHPS) linked data for survivors diagnosed between 2003 and 2011, with follow‐up claims data to 2017. Principal Findings: Within the 3‐year follow‐up period, 372/4516 survivors (mean age 75.1; 81.7% white) in the primary cohort (8.2%) died, 111 from cancer (2.5%), 665 (14.7%) experienced cancer recurrence, and 488 (10.8%) were hospitalized for adverse health outcomes. The algorithm's prediction resulted in 91.9% out‐of‐sample accuracy (the percent of observations classified correctly) and a 37.6% Cohen's Kappa (i.e., improvement over an uninformed model). Out‐of‐sample accuracy was 97.5% (44% improvement) for predicting cancer‐specific death, 85% (26% improvement) for recurrence, and 89% (28% improvement) for other adverse health outcomes. Important predictors across outcomes included geographic region, age, frailty, comorbidity, time since diagnosis, and out‐of‐pocket cost responsibility. Conclusions: Machine learning models accurately predicted relevant adverse survivorship outcomes, driven primarily by non‐cancer specific factors. Breast cancer survivors at high risk for adverse outcomes may benefit from more intensive care, whereas those at low risk may be more appropriately managed by primary care.
- 16 July 2025
- Published by Wiley in Health Services Research
- Vol. 61 (2) , e70005
Machine Learning Risk Stratification for Older Breast Cancer Survivors: Clinical Care Implications
Objective: To develop and validate a clinical risk prediction algorithm to identify breast cancer survivors at high risk for adverse outcomes. Study Setting and Design: Our national retrospective analysis used cross‐validated random forest machine learning models to separately predict the risk of all‐cause death, cancer‐specific death, claims‐derived risk of recurrence, and other adverse health outcomes within 3 and 5 years following treatment completion. Data Sources and Analytic Sample: Our study used the Surveillance and Epidemiology End Results (SEER) registry—Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey (SEER‐CAHPS) linked data for survivors diagnosed between 2003 and 2011, with follow‐up claims data to 2017. Principal Findings: Within the 3‐year follow‐up period, 372/4516 survivors (mean age 75.1; 81.7% white) in the primary cohort (8.2%) died, 111 from cancer (2.5%), 665 (14.7%) experienced cancer recurrence, and 488 (10.8%) were hospitalized for adverse health outcomes. The algorithm's prediction resulted in 91.9% out‐of‐sample accuracy (the percent of observations classified correctly) and a 37.6% Cohen's Kappa (i.e., improvement over an uninformed model). Out‐of‐sample accuracy was 97.5% (44% improvement) for predicting cancer‐specific death, 85% (26% improvement) for recurrence, and 89% (28% improvement) for other adverse health outcomes. Important predictors across outcomes included geographic region, age, frailty, comorbidity, time since diagnosis, and out‐of‐pocket cost responsibility. Conclusions: Machine learning models accurately predicted relevant adverse survivorship outcomes, driven primarily by non‐cancer specific factors. Breast cancer survivors at high risk for adverse outcomes may benefit from more intensive care, whereas those at low risk may be more appropriately managed by primary care.
- 17 June 2024
- Published by Springer Nature in Health Services and Outcomes Research Methodology
- Vol. 25 (2) , 166-181
Markets matter: a simulation study of the bias-variance trade-off in comparison group selection for difference-in-differences analysis
- 17 June 2024
- Published by Springer Nature in Health Services and Outcomes Research Methodology
- Vol. 25 (2) , 166-181
Markets matter: a simulation study of the bias-variance trade-off in comparison group selection for difference-in-differences analysis
Productivity costs associated with metastatic breast cancer in younger, midlife, and older women
Background: The objective of the current study was to estimate productivity costs due to metastatic breast cancer (mBC) via productive time lost among survivors and potential life‐years lost from premature mortality among 3 age groups: younger (aged 18‐44 years), midlife (aged 45‐64 years), and older (aged ≥65 years) women.Methods: The authors estimated the number of work and home productivity days missed due to mBC by age group using data from the 2000 to 2016 National Health Interview Survey. Years of potential life lost (YPLL) due to mBC were calculated for each age group using 2015 National Vital Statistics System data. The authors valued both sources of lost productivity time using the Current Population Survey and prior studies.Results: The per‐woman value of lost productive days (work and home) due to mBC ranged from $680 for older women to $5169 for younger women. In 2015, the value of lost work and home productivity days associated with mBC nationally was $67 million for younger women, $246 million for midlife women, and $66 million for older women. YPLL were highest among midlife women (403,786 life‐years), followed by older women (248,522 life‐years) and younger women (95,943 life‐years). Midlife women were found to have the highest market value of YPLL ($4.1 billion), followed by younger women ($1.6 billion) and older women ($527 million).Conclusions: The results of the current study demonstrated that mBC generates a high economic burden through lost productivity, especially among midlife women.
Productivity costs associated with metastatic breast cancer in younger, midlife, and older women
Background: The objective of the current study was to estimate productivity costs due to metastatic breast cancer (mBC) via productive time lost among survivors and potential life‐years lost from premature mortality among 3 age groups: younger (aged 18‐44 years), midlife (aged 45‐64 years), and older (aged ≥65 years) women.Methods: The authors estimated the number of work and home productivity days missed due to mBC by age group using data from the 2000 to 2016 National Health Interview Survey. Years of potential life lost (YPLL) due to mBC were calculated for each age group using 2015 National Vital Statistics System data. The authors valued both sources of lost productivity time using the Current Population Survey and prior studies.Results: The per‐woman value of lost productive days (work and home) due to mBC ranged from $680 for older women to $5169 for younger women. In 2015, the value of lost work and home productivity days associated with mBC nationally was $67 million for younger women, $246 million for midlife women, and $66 million for older women. YPLL were highest among midlife women (403,786 life‐years), followed by older women (248,522 life‐years) and younger women (95,943 life‐years). Midlife women were found to have the highest market value of YPLL ($4.1 billion), followed by younger women ($1.6 billion) and older women ($527 million).Conclusions: The results of the current study demonstrated that mBC generates a high economic burden through lost productivity, especially among midlife women.
- 26 April 2019
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 176 (2) , 445-451
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer
Background Factors influencing the adoption of genomic testing are poorly understood, which may lead to inequitable and suboptimal treatment in cancer patients. Oncotype DX (ODX) is one of the first and most widely used genomic assays to stratify risk in women with early-stage breast cancer (BC). Physician networks have emerged as a significant and modifiable driver of emerging medical technology adoption. Objective To investigate the association between physician network connections and the use of ODX testing. Methods A retrospective study of women diagnosed with BC using SEER-Medicare from 2008 to 2012 was used. Medical oncologists were “connected” if they shared two or more patients during the early-adoption period (2008–2009). Parallel physician- and patient-level analyses employed logistic mixed models to determine the impact of being “connected” to an early-adopting oncologist on ODX use in 2011–2012. Results 24,463 women met study criteria; 12,874 were diagnosed with BC in the early-adoption time period. 2129 medical oncologists treated these patients from 2008 to 2009. Medical oncologists had a median number of peer connections of 4 (IQR: 2–7). Peer connection to an early-adopting provider in 2008–2009 was associated with a 1.7-fold increase in providers’ adopting ODX (95% CI: 1.1–2.6) and a 1.5-fold increase in their patients receiving ODX (95% CI: 1.1–2.0) in 2010–2012. Conclusions Peer connectedness to an early-adopting physician predicts ODX adoption in both physician-level and patient-level analyses. Provider networks may provide a potent and modifiable means to modulate the diffusion of emerging medical technologies. Efforts to increase testing, where appropriate, may benefit from peer-to-peer-based connection strategies.
- 26 April 2019
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 176 (2) , 445-451
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer
Background Factors influencing the adoption of genomic testing are poorly understood, which may lead to inequitable and suboptimal treatment in cancer patients. Oncotype DX (ODX) is one of the first and most widely used genomic assays to stratify risk in women with early-stage breast cancer (BC). Physician networks have emerged as a significant and modifiable driver of emerging medical technology adoption. Objective To investigate the association between physician network connections and the use of ODX testing. Methods A retrospective study of women diagnosed with BC using SEER-Medicare from 2008 to 2012 was used. Medical oncologists were “connected” if they shared two or more patients during the early-adoption period (2008–2009). Parallel physician- and patient-level analyses employed logistic mixed models to determine the impact of being “connected” to an early-adopting oncologist on ODX use in 2011–2012. Results 24,463 women met study criteria; 12,874 were diagnosed with BC in the early-adoption time period. 2129 medical oncologists treated these patients from 2008 to 2009. Medical oncologists had a median number of peer connections of 4 (IQR: 2–7). Peer connection to an early-adopting provider in 2008–2009 was associated with a 1.7-fold increase in providers’ adopting ODX (95% CI: 1.1–2.6) and a 1.5-fold increase in their patients receiving ODX (95% CI: 1.1–2.0) in 2010–2012. Conclusions Peer connectedness to an early-adopting physician predicts ODX adoption in both physician-level and patient-level analyses. Provider networks may provide a potent and modifiable means to modulate the diffusion of emerging medical technologies. Efforts to increase testing, where appropriate, may benefit from peer-to-peer-based connection strategies.
- 28 January 2019
- Published by Wiley in Psycho-Oncology
- Vol. 28 (4) , 924-927
Can cancer care costs impact quality of life outcomes for the entire household?
- 28 January 2019
- Published by Wiley in Psycho-Oncology
- Vol. 28 (4) , 924-927
Can cancer care costs impact quality of life outcomes for the entire household?
- 30 May 2018
- Published by Wiley in Health Services Research
- Vol. 53 (6) , 4310-4331
Decomposing Mortality Disparities in Urban and Rural U.S. Counties
Objective: To understand the role of county characteristics in the growing divide between rural and urban mortality from 1980 to 2010.Data Source: Age‐adjusted mortality rates for all U.S. counties from 1980 to 2010 were obtained from the CDC Compressed Mortality File and combined with county characteristics from the U.S. Census Bureau, the Area Health Resources File, and the Inter‐University Consortium for Political and Social research.Study Design: We used Oaxaca–Blinder decomposition to assess the extent to which rural–urban mortality disparities are explained by observed county characteristics at each decade.Principal Findings: Decomposition shows that, at each decade, differences in rural/urban characteristics are sufficient to explain differences in mortality. Furthermore, starting in 1990, rural counties have significantly lower predicted mortality than urban counties when given identical county characteristics. We find changes in the effect of characteristics on mortality, not the characteristics themselves, drive the growing mortality divide.Conclusions: Differences in economic and demographic characteristics between rural and urban counties largely explain the differences in age‐adjusted mortality in any given year. Over time, the role these characteristics play in improving mortality has increased differentially for urban counties. As characteristics continue changing in importance as determinants of health, this divide may continue to widen.
- 30 May 2018
- Published by Wiley in Health Services Research
- Vol. 53 (6) , 4310-4331
Decomposing Mortality Disparities in Urban and Rural U.S. Counties
Objective: To understand the role of county characteristics in the growing divide between rural and urban mortality from 1980 to 2010.Data Source: Age‐adjusted mortality rates for all U.S. counties from 1980 to 2010 were obtained from the CDC Compressed Mortality File and combined with county characteristics from the U.S. Census Bureau, the Area Health Resources File, and the Inter‐University Consortium for Political and Social research.Study Design: We used Oaxaca–Blinder decomposition to assess the extent to which rural–urban mortality disparities are explained by observed county characteristics at each decade.Principal Findings: Decomposition shows that, at each decade, differences in rural/urban characteristics are sufficient to explain differences in mortality. Furthermore, starting in 1990, rural counties have significantly lower predicted mortality than urban counties when given identical county characteristics. We find changes in the effect of characteristics on mortality, not the characteristics themselves, drive the growing mortality divide.Conclusions: Differences in economic and demographic characteristics between rural and urban counties largely explain the differences in age‐adjusted mortality in any given year. Over time, the role these characteristics play in improving mortality has increased differentially for urban counties. As characteristics continue changing in importance as determinants of health, this divide may continue to widen.